Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Buflomedil is a non-selective antagonist of α-adrenergic receptors (α-ARs) and vasoactive compound.1,2,3,4 It binds to rat α1A- and α1B-ARs (Kis = 4.06 and 6.84 µM, respectively) and human platelet α2-ARs (IC50 = 1 µM) in radioligand binding assays.1,2 Buflomedil (0.06-60 µM) inhibits contraction of isolated canine saphenous veins induced by phenylephrine, clonidine (Item No. 15949), sympathetic nerve stimulation, or norepinephrine.3 It inhibits ADP-, collagen-, or epinephrine-induced aggregation of isolated human platelets when used at a concentration of 100 µM.2 Buflomedil (10 mg/kg) reduces hippocampal neuronal cell death in a rat model of carotid clamping-induced ischemia-reperfusion injury.4
WARNING This product is not for human or veterinary use.
1. Inhibitory effect of buflomedil on prostate α1A adrenoceptor in the Wistar rat. Neurosci. Lett. 367(2), 224-227 (2004).
2. In vitro studies of the effect of buflomedil on platelet responsiveness. Haemostasis 20(3), 181-191 (1990).
3. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 33(5), 430-460 (1987).
4. Protective effect of buflomedil in a rat model of moderate cerebral ischemia. Arzneimittelforschung. 55(8), 437-442 (2005).